Daito Pharmaceutical Co., Ltd. (JP:4577)
:4577
Want to see JP:4577 full AI Analyst Report?
4577 Stock Chart & Stats
¥1356.00
-¥13.00(-0.64%)
At close: 4:00 PM EST
¥1356.00
-¥13.00(-0.64%)
Day’s Range― - ―
52-Week Range¥982.00 - ¥1,521.00
Previous CloseN/A
Volume21.10K
Average Volume (3M)63.87K
Market Cap
¥34.24B
Enterprise Value¥42.94B
Total Cash (Recent Filing)¥2.15B
Total Debt (Recent Filing)¥11.94B
Price to Earnings (P/E)12.1
Beta0.29
Next Earnings
Jul 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)65.72
Shares Outstanding28,854,880
10 Day Avg. Volume54,390
30 Day Avg. Volume63,866
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.58
Price to Sales (P/S)0.59
P/FCF Ratio-31.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)86.7
Revenue Forecast (FY)¥54.30B
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing & API CapabilitiesA core manufacturing and contract services model provides durable revenue streams from long-term supply agreements with branded and generic customers. These capabilities create high operational barriers, recurring demand for scale and quality, and predictable production-led cash flows over the medium term.
Consistent Revenue GrowthSustained top-line growth signals continuing demand for the company’s products and services, supporting incremental scale economics and capacity utilization. Over 2–6 months this trend underpins ability to reinvest in operations and preserve competitive manufacturing position despite margin pressures.
Stable Equity Base & Positive Operating MarginsA stable capital structure plus positive EBIT/EBITDA margins indicate underlying operational viability and resilience. Even with margin contraction, positive operating profitability supports debt servicing, capital expenditures and continuity of operations without immediate recapitalization.
Bears Say
Declining Profit MarginsMaterial erosion in gross and net margins suggests sustained cost pressures or pricing weakness. Persistently lower margins reduce retained earnings and reinvestment capacity, weakening long-term competitiveness and making it harder to absorb input inflation or fund R&D and capacity expansion.
Rising LeverageAn increase in leverage reduces financial flexibility and raises interest burden risks. If leverage continues to climb while margins and cash flow weaken, the company could face constrained strategic choices, higher refinancing risk, and limited ability to fund growth or weather adverse demand shocks.
Negative Free Cash FlowPersistently negative free cash flow undermines the company’s capacity to fund capex, dividends, or debt repayments from operations. Over months this compels external financing, increases cost of capital, and constrains strategic investments needed to restore margins or expand contract-manufacturing capacity.
Daito Pharmaceutical Co., Ltd. News
4577 FAQ
What was Daito Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daito Pharmaceutical Co., Ltd. lowest stock price was ¥982.00 and its highest was ¥1521.00 in the past 12 months.
What is Daito Pharmaceutical Co., Ltd.’s market cap?
Daito Pharmaceutical Co., Ltd.’s market cap is ¥34.24B.
When is Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date is Jul 10, 2026 which is in 19 days.
How were Daito Pharmaceutical Co., Ltd.’s earnings last quarter?
Daito Pharmaceutical Co., Ltd. released its earnings results on Apr 10, 2026. The company reported ¥35.21 earnings per share for the quarter, beating the consensus estimate of N/A by ¥35.21.
Is Daito Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daito Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Daito Pharmaceutical Co., Ltd. pay dividends?
Daito Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥20 which represents an annual dividend yield of 2.75%. See more information on Daito Pharmaceutical Co., Ltd. dividends here
What is Daito Pharmaceutical Co., Ltd.’s EPS estimate?
Daito Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daito Pharmaceutical Co., Ltd. have?
Daito Pharmaceutical Co., Ltd. has 28,854,880 shares outstanding.
What happened to Daito Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Daito Pharmaceutical Co., Ltd. reported an EPS of ¥35.21 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.095%.
Which hedge fund is a major shareholder of Daito Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4577
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.
Technical Analysis
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---